French Firm Explores U.S. Regulatory Strategy For Blood-based Alzheimer’s Test
This article was originally published in The Gray Sheet
Executive Summary
With a CE mark in hand, Exonhit is training its sights on the U.S. market. A 160-patient pilot study conducted through the Cleveland Clinic completed enrollment a few weeks ago.
You may also be interested in...
HHS Gives Nod To Diagnostics In Healthy People 2020 Initiative
More people would be screened for health conditions ranging from diabetes to colorectal cancer to sleep apnea over the next decade under goals set out in HHS’ recent “Healthy People 2020” initiative.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.